Navigation Links
Carrington Subsidiary DelSite to Present at International Vaccine Conference in Ireland
Date:10/3/2007

Key Presentation by Dr. Yawei Ni, DelSite's CSO, Will Detail Antigen

Sparing and Immunoenhancing Attributes of GelSite(R) Polymer

IRVING, Texas, Oct. 3 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (Pink Sheets: CARN) today announced that Dr. Yawei Ni, Chief Scientific Officer of DelSite Biotechnologies, Inc., Carrington's wholly-owned subsidiary, will make an key presentation titled "An Effective Adjuvant Based on a Novel In-situ Gelling Anionic Polysaccharide (GelSite(R) Polymer)" on November 13, 2007, at the second International Conference on Modern Vaccines/Adjuvants Formulation (MVAF) in Dublin, Ireland.

GelSite(R) polymer is a chemically and functionally distinct polygalacturonic acid (sodium salt) produced under cGMP to a purity of > 99%. It is uniquely capable of gelling in-situ at the administration site upon contact with body fluids at low polymer concentrations providing a sustained release mechanism of the active component. It is highly suited for the delivery of vaccines and therapeutics.

The presentation will discuss details of GelSite(R) polymer's immunoenhancing and antigen sparing effect following intramuscular injection. The GelSite(R) polymer is inert and non-immunostimulatory, but achieves its immunoenhancing and antigen-sparing effect through sustained release of vaccine antigens conferred by the in-situ gelation. It potentially represents a new class of adjuvants that act through the sustained release mechanism, rather than by immunostimulation.

Vaccines, one of the fast growing pharmaceutical segments, are projected to account for greater than $20 billion in sales in the next few years. Adjuvants are a critical component for vaccine development. Vaccines in a wide range of areas including infectious diseases and cancers are being developed by various companies, many of which will require adjuvants for optimal performance.

About MVAF 2007

MVAF 2007 will be an international forum for researchers and contributors from academic programs, industrial, governmental and regulatory groups interested in the future development and design of vaccines and adjuvants. The scientific program will include keynote lectures, contributed papers, workshops, panel discussions and poster presentations emphasizing all aspects of the usage and effectiveness of pharmaceutical development of vaccines and adjuvants, national and international regulatory guidelines, and safety issues with special emphasis on delivery/administration issues.

About DelSite

Carrington's wholly-owned subsidiary DelSite Biotechnologies, Inc., is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs and vaccines. DelSite is currently developing a nasal powder vaccine using its GelVac(TM) formula with the H5N1 avian flu antigen. This work is partially funded by two grants from NIAID (National Institute of Allergy and Infectious Diseases) of NIH (National Institute of Health) under the Department of Health and Human Services.

About Carrington

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com.

Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission.


'/>"/>
SOURCE Carrington Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. DelSite Working Toward Solving Delivery of Influenza Vaccine in Pandemic Situations
2. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
3. Researchers Present Ways To Reduce The Risk Of Dementia
4. Researchers Present Data Regarding The Efficiency Of Herbs
5. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
6. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
7. Drug Reactions First Present Themselves In The Mouth
8. Reminiscing Into The Past Makes You Dissatisfied With The Present
9. Living In The Past Indicates Dissatisfaction With Present
10. Movies Represent Coma In A Wrong Way
11. Onchocerciasis: Presentation And Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , ... February 24, 2017 , ... ... Charlevoix, once again hosted their Military Wedding Giveaway, with the winning couple announced ... Castle Farms with services generously donated from local vendors: A Matter of Taste, ...
(Date:2/23/2017)... ... 23, 2017 , ... On February 22, 2017 the U.S. ... to withdraw previous guidance issued by the Obama Administration requiring schools to treat ... 2016 by the Obama Administration came in response to a growing number of ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... return to the La Gorce Country Club in Miami Beach to host its ...
(Date:2/23/2017)... ... , ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased to announce KLS ... longtime supporter of the event. , "We are pleased that KLS Martin is joining ... 2017 ACPA President. "KLS Martin has a long track record of support of the ...
(Date:2/23/2017)... ... 2017 , ... Hamlin Dental Group and Dr. Hamid Reza, dentist in ... the month of February, patients who visit Hamlin Dental Group will receive a ticket ... two at the Cheesecake Factory. , Tickets are available for routine dental visits ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Research and Markets has announced the addition of the "Menopause ... ... Drugs Price Analysis and Strategies - 2016, provides drug pricing data and ... questions: What are the key drugs marketed ... Global Menopause market? What are the unit prices and ...
(Date:2/23/2017)... Feb. 23, 2017 Research and Markets has ... Strategies - 2016" report to their offering. ... The latest research Fibromyalgia Drugs ... benchmarks in the global Fibromyalgia market. The research answers ... drugs marketed for Fibromyalgia and their clinical attributes? How are they ...
(Date:2/23/2017)... , February 23, 2017 Obese ... increasing caseload for varicose veins in their body. The ... are prompting the adoption of endovenous laser therapy for ... endovenous laser therapy market, published by Future ... lifestyle choices and consequences of obesity have collectively factored ...
Breaking Medicine Technology: